Evofem Biosciences amends debt maturity terms with Adjuvant
Evofem Biosciences amended its Adjuvant convertible promissory notes agreement on October 9, 2026, setting maturity at December 1, 2026. Earlier repayment applies upon a change of control at Adjuvant’s election or acceleration under the agreement. Prepayment before December 1, 2026, requires Adjuvant’s prior written co